Proteasome inhibitors in the treatment of multiple myeloma

ISSN： 1473-7140

Source： Expert Review of Anticancer Therapy, Vol.13, Iss.3, 2013-03, pp. : 339-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells

Molecular Medicine Reports, Vol. 10, Iss. 5, 2014-01 ,pp. : 2609-2612

Spandidos Publications

Access to resources Recommend Favorite

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells

International Journal of Oncology, Vol. 46, Iss. 3, 2015-01 ,pp. : 963-972

Spandidos Publications

Access to resources Recommend Favorite

Pomalidomide in the treatment of relapsed multiple myeloma

By Forsberg Peter A Mark Tomer M

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 939-948

Future Medicine

Access to resources Recommend Favorite

Treatment of Multiple Myeloma: Current Management and New Approaches

By Ho P.J. Gibson J. Joshua D.E.

American Journal of Cancer, Vol. 3, Iss. 1, 2004-01 ,pp. : 47-66

Adis International

Access to resources Recommend Favorite

Treatment Approaches for Relapsing and Refractory Multiple Myeloma

By Bladé Joan Esteve Jordi

Acta Oncologica, Vol. 39, Iss. 7, 2000-11 ,pp. : 843-847

Informa Healthcare

Access to resources Recommend Favorite